Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia

scientific article published on 9 June 2015

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1001340407
P356DOI10.1038/LEU.2015.138
P932PMC publication ID4610040
P698PubMed publication ID26055303

P50authorJohannes ZuberQ47713758
Gregor EisenwortQ50623922
Gregor HoermannQ50930011
Peter ValentQ56697676
Harald HerrmannQ56940149
Irina SadovnikQ56979840
Emir HadzijusufovicQ38327164
P2093author name stringD Radia
A Reiter
J E Bradner
T Hoffmann
W R Sperr
H-P Horny
M Arock
L Müllauer
K Blatt
G Wedeh
J Schwaab
S Cerny-Reiterer
P2860cites workBromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localizationQ24561478
One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probesQ24685763
BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domainQ28116760
BET domain co-regulators in obesity, inflammation and cancerQ28269301
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaQ29617201
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factorsQ33384073
Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasmQ70972826
Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosisQ73936505
Systemic mastocytosisQ75343552
The histone code and treatments for acute myeloid leukemiaQ83590327
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorderQ33784323
Diagnostic criteria and classification of mastocytosis: a consensus proposalQ33948617
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaQ34033206
Mast cell leukemia: report of a case and review of the literatureQ34165793
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.Q34264299
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.Q34293285
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosisQ34612654
Mastocytosis: state of the art.Q34641105
An optimized microRNA backbone for effective single-copy RNAiQ35065928
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaQ35101794
Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.Q35829710
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.Q35848377
On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Q35854970
KIT mutations in mastocytosis and their potential as therapeutic targetsQ36576453
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteriaQ36835061
Mast cells and mastocytosisQ36835143
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.Q36926120
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.Q37462729
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cellsQ37585215
Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.Q37810130
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Q37884959
Targeting epigenetic readers in cancer.Q38034797
Mast cell leukemiaQ38067698
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit productQ38315689
A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfectionQ39010730
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.Q39033630
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinibQ39523051
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.Q39606792
Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cellsQ39782974
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.Q40048837
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosisQ40325513
Establishment of an immature mast cell line from a patient with mast cell leukemiaQ41296878
Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.Q43622703
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kitQ44539087
Comprehensive mutational profiling in advanced systemic mastocytosisQ46716443
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effectsQ46724516
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophilsQ46818989
P433issue11
P921main subjectmast cellQ191989
P304page(s)2230-2237
P577publication date2015-06-09
P1433published inLeukemiaQ6534498
P1476titleIdentification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia
P478volume29

Reverse relations

cites work (P2860)
Q90292270CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis
Q58617727Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma
Q48104415Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Q64103896In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis
Q41771583Inhibition of the BET family of epigenetic reader proteins: A novel principle for modulating gene expression in IgE-activated mast cells
Q38777126Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Q47930594Midostaurin: a magic bullet that blocks mast cell expansion and activation
Q59810100Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
Q41061871Targeted Treatment Options in Mastocytosis

Search more.